Key Takeaways Ashland's Q4 profit rose to $32M from $16M YoY, though adjusted EPS fell short of estimates.Sales declined 8% year over year to $478M, weighed by divestitures.The company expects full-year fiscal 2026 adjusted EBITDA to be $400-$430 million.Ashland Global Holdings Inc. (ASH) recorded a profit of $32 million or 71 cents per share for the fourth-quarter fiscal 2025 (ended Sept. 30, 2025) compared with a profit of $16 million or 33 cents in the prior-year quarter. Barring one-time items, adjusted ...

Ashland (NYSE:ASH) Q4 2025 Earnings Call November 05, 2025 10:00 AM ET Speaker0Good day, and thank you for standing by. Welcome to Ashland's fourth quarter fiscal year 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw y ...

earnings conference call fourth quarter fiscal 2025 November 5, 2025 — Forward-Looking Statements — This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as "anticipates," "believes," "expects," "estimates," "is likely," "predicts," "projects," "forecasts," "objectives," "may," "will," ...

Novo continued, "Life Sciences sustained momentum in pharma, driven by innovation and healthy demand for high-value excipients, injectables, and tablet coatings. Personal Care delivered strong growth and benefited from recent strategic investments, with robust performance across end markets and regions. For Specialty Additives, sequential coatings stability across regions continued to reflect portfolio strength and disciplined execution. Demand remained soft in China and North America, contributing to a yea ...

  Sales of $478 million, down eight percent from the prior-year quarterPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC), Nutraceuticals and Avoca portfolio optimization initiatives (collectively, Portfolio Optimization) reduced overall sales by approximately $38 million or seven percent versus the prior-year quarter. Excluding these initiatives, sales declined one percentIncome from continuing operations of $33 million, or $0.73 per diluted shareAdjusted Income from Continuing Operati ...

Core Insights - Ascentage Pharma Group International announced that results from two clinical studies of its drug, lisaftoclax, have been selected for presentations at the 67th American Society of Hematology (ASH) Annual Meeting, marking the fourth consecutive year for such recognition [1][2] - The company is focused on addressing unmet medical needs in cancer through the development of novel therapies, with multiple investigational drug candidates being presented at the ASH Annual Meeting [1][4] Company Overview - Ascentage Pharma is a global, commercial stage biopharmaceutical company engaged in the discovery, development, and commercialization of differentiated therapies for cancer [16] - The company has a robust pipeline that includes inhibitors targeting key proteins in the apoptotic pathway and next-generation kinase inhibitors [16][19] Drug Development and Clinical Trials - Lisaftoclax, an orally available Bcl-2 inhibitor, has shown efficacy in treating hematologic malignancies and is currently being commercialized in China for CLL/SLL patients who have received prior systemic therapy [2][18] - The company is conducting four global registrational Phase III studies for lisaftoclax, including trials in combination with BTK inhibitors and studies targeting newly diagnosed patients [18] ASH Annual Meeting Presentations - At the ASH Annual Meeting, Ascentage Pharma will present an oral report on a Phase II study of lisaftoclax monotherapy for relapsed/refractory CLL/SLL, and a poster on its combination with azacitidine in newly diagnosed or prior venetoclax-exposed myeloid malignancies [2][12] - The presentations will highlight the clinical efficacy and safety profiles of the drug candidates, reinforcing the company's commitment to innovation in cancer treatment [4][11] Efficacy and Safety Results - In a pivotal Phase II study of lisaftoclax, the objective response rate (ORR) was 62.5% among 72 evaluable patients with R/R CLL/SLL, with a median progression-free survival of 23.89 months [9][11] - The safety profile of lisaftoclax was manageable, with frequent grade ≥3 treatment-related adverse events primarily being hematologic toxicities [10][11] Future Directions - Ascentage Pharma aims to accelerate its clinical development programs to provide more treatment options for patients, with ongoing evaluations of its drug candidates in various hematologic malignancies [4][15]

ROCKVILLE, Md. and SUZHOU, China, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that the latest results from multiple clinical studies of its novel drug, olverembatinib (HQP1351), have been selected for presentations at the 67th American Soci ...

NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical data on rusfertide in polycythemia vera, including the Phase 3 VERIFY study, will be the focus of four presentations at the 67th Annual American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida, from December 6-9, 2025. ASH Presentation Details: Presenting Author: Andrew Kuykendall, MD (Moffitt Cancer Center) Publication Number: 81 Title: ...

Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma Two abstracts featuring new Phase 2 data highlight the potential of CAR-T cell therapy candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma Results demonstrate high rates of complete and durable responses along with low rates of high-grade toxicities using GLPG5101 manufactured on innovative median seven-day vein-to-vein time platform, potentially enabling broader acc ...

LUND, SE / ACCESS Newswire / November 3, 2025 / BioInvent International AB ("BioInvent")(STO:BINV) (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in- class immune-modulatory antibodies for cancer immunotherapy, today announced that it will present new data from the safety run-in portion of its ongoing trial evaluating BI-1206 in combination with rituximab and Calquence ® (acalabrutinib) for the treatment of non-Hodgkin's lymphoma (NHL) in a poster at t ...